Chicago Capital LLC Has $52.66 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Chicago Capital LLC lifted its holdings in Zoetis Inc. (NYSE:ZTS) by 0.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 323,234 shares of the company’s stock after purchasing an additional 723 shares during the period. Zoetis accounts for about 1.4% of Chicago Capital LLC’s investment portfolio, making the stock its 29th biggest holding. Chicago Capital LLC owned approximately 0.07% of Zoetis worth $52,664,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Darwin Wealth Management LLC bought a new position in Zoetis in the 3rd quarter worth $31,000. First Personal Financial Services bought a new position in Zoetis in the 3rd quarter worth $33,000. Capital Performance Advisors LLP bought a new position in Zoetis in the 3rd quarter worth $33,000. Dunhill Financial LLC raised its holdings in Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares during the period. Finally, Quarry LP raised its holdings in Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after acquiring an additional 153 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Down 1.1 %

ZTS opened at $170.81 on Monday. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The company has a market cap of $77.06 billion, a price-to-earnings ratio of 32.11, a price-to-earnings-growth ratio of 2.72 and a beta of 0.90. The firm has a 50 day simple moving average of $169.62 and a 200 day simple moving average of $179.46. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53.

Zoetis (NYSE:ZTS) last issued its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the prior year, the firm earned $1.36 earnings per share. The business’s quarterly revenue was up 11.6% on a year-over-year basis. On average, sell-side analysts anticipate that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.17%. The ex-dividend date is Tuesday, January 21st. This is an increase from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s dividend payout ratio is presently 37.59%.

Analysts Set New Price Targets

ZTS has been the topic of several research reports. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Morgan Stanley dropped their price objective on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. JPMorgan Chase & Co. boosted their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Stifel Nicolaus dropped their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Finally, Leerink Partners started coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Zoetis presently has an average rating of “Buy” and a consensus price target of $215.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.